冠状动脉疾病是代谢功能障碍相关性脂肪性肝病和肝纤维化的危险因素。

IF 3.7 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Annals of hepatology Pub Date : 2024-05-06 DOI:10.1016/j.aohep.2024.101511
Luis Vega , Daniela Simian , Abraham I. Gajardo , Marcelo Salinas , Andrea Urra , Máximo Cattaneo , Rosario Pino , Juan P. Roblero , Álvaro Urzúa , Katherine Rojas , Jaime Poniachik
{"title":"冠状动脉疾病是代谢功能障碍相关性脂肪性肝病和肝纤维化的危险因素。","authors":"Luis Vega ,&nbsp;Daniela Simian ,&nbsp;Abraham I. Gajardo ,&nbsp;Marcelo Salinas ,&nbsp;Andrea Urra ,&nbsp;Máximo Cattaneo ,&nbsp;Rosario Pino ,&nbsp;Juan P. Roblero ,&nbsp;Álvaro Urzúa ,&nbsp;Katherine Rojas ,&nbsp;Jaime Poniachik","doi":"10.1016/j.aohep.2024.101511","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are at an increased cardiovascular risk. On the contrary, non-alcoholic fatty liver disease (NAFLD) is highly prevalent in patients with coronary heart disease (CHD). However, it is not known whether patients with significant CHD show a higher frequency of liver fibrosis. This study aimed to determine the frequency of MASLD and liver fibrosis in patients with CHD and to assess whether coronary stenosis is significantly associated with MASLD and fibrosis.</p></div><div><h3>Patients and Methods</h3><p>This observational and analytical study included adult patients without any known liver disease who underwent coronary angiography for suspected coronary artery disease (Jul 2021–Jul 2022). The presence of significant CHD (&gt; 50% stenosis of at least one coronary artery) was determined. Liver elastography (FibroScan®) was performed up to 6 months after the coronary angiographic study to determine liver fibrosis, a measurement of liver stiffness (&gt; 6.5 Kpa). Fisher's test, Mann–Whitney U test, and logistic regression models were used (<em>p</em> &lt; 0.05).</p></div><div><h3>Results</h3><p>The study included 113 patients (76% men, average age: 63 years [standard deviation: 9.9]), of which 72% presented with significant CHD. The prevalence rate of MASLD was 52%. Liver fibrosis was present in 12% of the patients and all patients in the significant CHD group (<em>p</em> = 0.007). An increase in the number of vessels with significant CHD increased the probability of liver fibrosis (odds ratio, 1.79; 95% confidence interval, 1.06–3.04; <em>p</em> = 0.029).</p></div><div><h3>Conclusions</h3><p>MASLD is highly prevalent in patients with significant CHD but without known liver damage. These data suggest that MASLD and liver fibrosis should be investigated in patients with CHD. The presence of confounding variables, especially the presence of type 2 diabetes mellitus, should be evaluated in further studies.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 4","pages":"Article 101511"},"PeriodicalIF":3.7000,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268124003053/pdfft?md5=c271d26aa405e8ebd80dc477a0ce94e7&pid=1-s2.0-S1665268124003053-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis\",\"authors\":\"Luis Vega ,&nbsp;Daniela Simian ,&nbsp;Abraham I. Gajardo ,&nbsp;Marcelo Salinas ,&nbsp;Andrea Urra ,&nbsp;Máximo Cattaneo ,&nbsp;Rosario Pino ,&nbsp;Juan P. Roblero ,&nbsp;Álvaro Urzúa ,&nbsp;Katherine Rojas ,&nbsp;Jaime Poniachik\",\"doi\":\"10.1016/j.aohep.2024.101511\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction and Objectives</h3><p>Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are at an increased cardiovascular risk. On the contrary, non-alcoholic fatty liver disease (NAFLD) is highly prevalent in patients with coronary heart disease (CHD). However, it is not known whether patients with significant CHD show a higher frequency of liver fibrosis. This study aimed to determine the frequency of MASLD and liver fibrosis in patients with CHD and to assess whether coronary stenosis is significantly associated with MASLD and fibrosis.</p></div><div><h3>Patients and Methods</h3><p>This observational and analytical study included adult patients without any known liver disease who underwent coronary angiography for suspected coronary artery disease (Jul 2021–Jul 2022). The presence of significant CHD (&gt; 50% stenosis of at least one coronary artery) was determined. Liver elastography (FibroScan®) was performed up to 6 months after the coronary angiographic study to determine liver fibrosis, a measurement of liver stiffness (&gt; 6.5 Kpa). Fisher's test, Mann–Whitney U test, and logistic regression models were used (<em>p</em> &lt; 0.05).</p></div><div><h3>Results</h3><p>The study included 113 patients (76% men, average age: 63 years [standard deviation: 9.9]), of which 72% presented with significant CHD. The prevalence rate of MASLD was 52%. Liver fibrosis was present in 12% of the patients and all patients in the significant CHD group (<em>p</em> = 0.007). An increase in the number of vessels with significant CHD increased the probability of liver fibrosis (odds ratio, 1.79; 95% confidence interval, 1.06–3.04; <em>p</em> = 0.029).</p></div><div><h3>Conclusions</h3><p>MASLD is highly prevalent in patients with significant CHD but without known liver damage. These data suggest that MASLD and liver fibrosis should be investigated in patients with CHD. The presence of confounding variables, especially the presence of type 2 diabetes mellitus, should be evaluated in further studies.</p></div>\",\"PeriodicalId\":7979,\"journal\":{\"name\":\"Annals of hepatology\",\"volume\":\"29 4\",\"pages\":\"Article 101511\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-05-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1665268124003053/pdfft?md5=c271d26aa405e8ebd80dc477a0ce94e7&pid=1-s2.0-S1665268124003053-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1665268124003053\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1665268124003053","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

导言和目标:代谢功能障碍相关性脂肪性肝病(MASLD)患者的心血管风险增加。相反,非酒精性脂肪肝(NAFLD)在冠心病(CHD)患者中发病率很高。然而,尚不清楚患有严重冠心病的患者是否会出现更高频率的肝纤维化。本研究旨在确定冠心病患者中MASLD和肝纤维化的发生频率,并评估冠状动脉狭窄是否与MASLD和肝纤维化显著相关:这项观察和分析研究纳入了无任何已知肝病的成年患者,这些患者因怀疑患有冠状动脉疾病而接受了冠状动脉造影术(2021年7月至2022年7月)。确定是否存在明显的冠心病(至少一条冠状动脉狭窄>50%)。在冠状动脉造影检查后 6 个月内进行肝脏弹性成像(FibroScan®),以确定肝脏纤维化程度,这是肝脏硬度(> 6.5 Kpa)的测量值。采用了费雪检验、曼-惠特尼 U 检验和逻辑回归模型(pResults:研究共纳入 113 名患者(76% 为男性,平均年龄:63 岁[标准差:9.9]),其中 72% 的患者伴有明显的心脏病。MASLD的发病率为52%。12%的患者存在肝纤维化,而在严重心脏病组中,所有患者都存在肝纤维化(P=0.007)。伴有明显冠状动脉缺血的血管数量的增加会增加肝纤维化的几率(几率比,1.79;95% 置信区间,1.06-3.04;P=0.029):MASLD在有明显心脏病但未发现肝损伤的患者中发病率很高。这些数据表明,MASLD 和肝纤维化应在冠心病患者中进行调查。在进一步的研究中,应评估是否存在混杂变量,尤其是是否存在2型糖尿病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis

Introduction and Objectives

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are at an increased cardiovascular risk. On the contrary, non-alcoholic fatty liver disease (NAFLD) is highly prevalent in patients with coronary heart disease (CHD). However, it is not known whether patients with significant CHD show a higher frequency of liver fibrosis. This study aimed to determine the frequency of MASLD and liver fibrosis in patients with CHD and to assess whether coronary stenosis is significantly associated with MASLD and fibrosis.

Patients and Methods

This observational and analytical study included adult patients without any known liver disease who underwent coronary angiography for suspected coronary artery disease (Jul 2021–Jul 2022). The presence of significant CHD (> 50% stenosis of at least one coronary artery) was determined. Liver elastography (FibroScan®) was performed up to 6 months after the coronary angiographic study to determine liver fibrosis, a measurement of liver stiffness (> 6.5 Kpa). Fisher's test, Mann–Whitney U test, and logistic regression models were used (p < 0.05).

Results

The study included 113 patients (76% men, average age: 63 years [standard deviation: 9.9]), of which 72% presented with significant CHD. The prevalence rate of MASLD was 52%. Liver fibrosis was present in 12% of the patients and all patients in the significant CHD group (p = 0.007). An increase in the number of vessels with significant CHD increased the probability of liver fibrosis (odds ratio, 1.79; 95% confidence interval, 1.06–3.04; p = 0.029).

Conclusions

MASLD is highly prevalent in patients with significant CHD but without known liver damage. These data suggest that MASLD and liver fibrosis should be investigated in patients with CHD. The presence of confounding variables, especially the presence of type 2 diabetes mellitus, should be evaluated in further studies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Annals of hepatology
Annals of hepatology 医学-胃肠肝病学
CiteScore
7.90
自引率
2.60%
发文量
183
审稿时长
4-8 weeks
期刊介绍: Annals of Hepatology publishes original research on the biology and diseases of the liver in both humans and experimental models. Contributions may be submitted as regular articles. The journal also publishes concise reviews of both basic and clinical topics.
期刊最新文献
Editorial board Global multi-societies endorsement of the MAFLD definition An Acknowledgement Biological aging accelerates hepatic fibrosis: Insights from the NHANES 2017-2020 and genome-wide association study analysis. Development of a biodegradable prosthesis through tissue engineering, for the organ-replacement or substitution of the extrahepatic bile duct
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1